Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
With a market cap of 20.46B, Incyte(INCY) trades at $104.24. The stock has a price-to-earnings ratio of 17.73.
During the trading session on 2025-11-06, Incyte(INCY) shares reached a daily high of $107.03 and a low of $103.53. At a current price of $104.24, the stock is +0.7% higher than the low and still -2.6% under the high.
Trading activity shows a volume of 737.22K, compared to an average daily volume of 3.58M.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $107.03 and a low of $53.56.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $107.03 and a low of $53.56.
INCY News
On November 3, 2025, Prelude Therapeutics announced a private placement, raising US$25,000,000 by issuing 6,250,000 shares at US$4 each, with participation from...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Piper Sandler analyst Allison Bratzel raised the firm’s price target on Incyte (INCY) to $102 from $82 and keeps an Overweight rating on the shares. The firm no...
Analyst ratings
52%
of 29 ratingsMore INCY News
Prelude Therapeutics (PRLD) stock plummeted on Tuesday after the biopharmaceutical company announced an exclusive options agreement with biopharmaceutical compa...
Prelude Therapeutics (PRLD) is providing a number of strategic updates, including its recently executed option agreement with Incyte Corporation (INCY) centered...
After Incyte’s (INCY) abstract of preliminary data from INCB0989 in myelofibrosis was posted on the ASH 2025 website, Mizuho believes the efficacy data look “pr...
William Blair analyst Matt Phipps has maintained their neutral stance on INCY stock, giving a Hold rating on October 29. Elevate Your Investing Strategy: Take a...
Guggenheim analyst Michael Schmidt upgraded Incyte (INCY) to Buy from Neutral with a $125 price target Published first on TheFly – the ultimate source for real...
Incyte reported strong third-quarter 2025 results on October 28, with revenue rising to US$1.37 billion and net income reaching US$424.17 million, and raised it...